How to Help Your Patients Find Breztri in Stock: A Provider's Guide

When a patient calls your office unable to fill their Breztri Aerosphere prescription, it creates a clinical and administrative burden for your team. Breztri is a triple-combination ICS/LAMA/LABA inhaler — the right therapy for many COPD and asthma patients, but not always the easiest to access. This provider guide gives you a practical, actionable framework for helping your patients navigate stock issues, insurance barriers, and cost hurdles so they stay on therapy.

Step 1: Triage Why the Patient Can't Fill Breztri

Before taking action, identify the root cause. Most Breztri access issues fall into one of three categories:

Stock unavailability: The pharmacy doesn't have the inhaler in stock. Solution: locate an alternative pharmacy.

Insurance/prior auth issue: Authorization is pending, denied, or the patient hasn't met step therapy. Solution: prior auth submission or appeal.

Cost barrier: The patient can't afford the copay or cash price. Solution: savings programs or alternative therapy.

A quick phone triage with your medical assistant can categorize the issue and route it to the appropriate team member — saving both time and patient stress.

Step 2: Direct Stock-Issue Patients to medfinder

For patients who simply can't find Breztri in stock at a nearby pharmacy, recommend medfinder. medfinder calls pharmacies on the patient's behalf to locate which ones have the medication in stock, then texts results directly to the patient. This eliminates the burden of patients calling dozens of pharmacies themselves — a major source of non-adherence when access is difficult.

You can include medfinder.com on your patient education materials or have your MA mention it when triaging Breztri fill complaints.

Step 3: Proactively Submit Prior Authorizations

For new Breztri prescriptions, submit prior authorization at the time of prescribing — not after the patient hits the pharmacy. A proactive approach reduces the chance your patient goes without their inhaler during the auth process. Key documentation elements:

Confirmed COPD or asthma diagnosis with spirometry data (FEV1/FVC ratio < 0.70, FEV1 % predicted)

Exacerbation history: number and severity of events in the prior 12 months

Previous dual-therapy regimens tried, with dates and clinical response (or lack thereof)

Blood eosinophil count: ≥ 300 cells/mcL strengthens the ICS rationale; ≥ 100 cells/mcL with exacerbation history supports approval

If the initial prior auth is denied, request a peer-to-peer review and reference the ETHOS trial data (24% exacerbation reduction vs. LAMA/LABA, rate ratio 0.76).

Step 4: Connect Cost-Barrier Patients With Savings Programs

When cost is the barrier, equip your patients with these specific resources:

Breztri Zero Pay (commercial insurance): Patients with commercial insurance may pay $0 per fill. Apply at breztri.com or by calling AstraZeneca. Excludes Medicare, Medicaid, and Tricare beneficiaries.

AZ&Me Patient Assistance Program: For uninsured or Medicare patients meeting income criteria. Provides Breztri at no charge. Call 1-800-292-6363. Your office can also complete the enrollment paperwork on the patient's behalf.

GoodRx / SingleCare coupons: Even without insurance, GoodRx can bring Breztri down to ~$655–$674 per inhaler at select pharmacies. SingleCare may offer lower prices at certain locations (~$572). Not ideal for long-term use given the cash price, but helpful as a bridge.

Step 5: Know When to Bridge With an Alternative

If a patient cannot access Breztri within 48–72 hours and is running low, don't let them go without maintenance therapy. Consider these clinical bridges:

Trelegy Ellipta: ICS/LAMA/LABA triple therapy, once daily, may be stocked where Breztri is not

Generic budesonide/formoterol (generic Symbicort) + tiotropium bromide (Spiriva): affordable two-inhaler triple therapy

Office samples: Ask your AstraZeneca representative about Breztri sample availability for patients during coverage gaps

Step 6: Set Up Proactive Refill Systems

The simplest way to prevent Breztri access crises is proactive refill management. At the end of every Breztri-related visit:

Send a refill 10–14 days before the patient's supply runs out

Encourage patients to set up 90-day mail-order fills if their plan allows it

Have a standard refill protocol in your EHR that flags Breztri refills 2 weeks before the expected run-out date

For a broader overview of the supply landscape and clinical context, see our Breztri shortage update for providers.